newsfilter
← Latest News
Business Wire·

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – Ironwood